Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Non-Small Cell Lung Cancer
Novel Targeted Therapies and Immunotherapies for Metastatic Non-small Cell Lung Cancer (NSCLC)
Targeted therapies and immunotherapies improve outcomes and quality of life for patients with metastatic NSCLC who have specific biomarkers. With the rapid pace of the new FDA approvals and subsequent revisions in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer, it has become challenging to stay current with the new NCCN recommendations for sequencing therapy with targeted agents and immunotherapies. Clinicians need to be aware of the most current recommendations for managing patients with metastatic NSCLC so they can provide the most appropriate care.
This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Describe the different types of biomarker testing used to determine whether patients with metastatic NSCLC are candidates for targeted therapy or immunotherapy.
- Select the most appropriate first-line therapy option for patients with metastatic NSCLC who have specific biomarkers.
- Discuss subsequent therapy options for patients with metastatic NSCLC who have biomarkers and have progressed on first-line therapy.
Sandip P. Patel, MD
UC San Diego Moores Cancer Center
Grace Lin, MD, PhD
UC San Diego Moores Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category 1 credit for completing this activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program.
|National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: TBD
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Click the Take Course button to register for this upcoming live webinar.
This webinar will be presented live one time only on Thursday, October 25, 2018, from 1:00 - 2:00 PM Eastern Daylight Time (EDT) (UTC -4). To convert the start time of this webinar for other time zones, click here.
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing